Mashup Score:230
American Association for Cancer Research(R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage - 3 days
Mashup Score:230
Specialty: Hematology/Oncology News
Mashup Score:230
American Association for Cancer Research(R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage - 5 days
Mashup Score:230
Summary:. Social media (SoMe) platforms have the ability to strengthen the oncology community, leading to intellectual connections that with time develop into friendships. SoMe...
-
The oncology community is growing stronger with the power of social media! 💻 https://t.co/3E5Si71Ef1 https://t.co/3E5Si71Ef1 - view on twitter
Mashup Score:227
American Association for Cancer Research(R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage - 7 days
Mashup Score:227
Summary:. Social media (SoMe) platforms have the ability to strengthen the oncology community, leading to intellectual connections that with time develop into friendships. SoMe...
-
The oncology community is growing stronger with the power of social media! 💻 Network, Connect with others, share experiences, and access the latest information on treatment and research🧬 Together, we are stronger💪 @OncoAlert 🚨 FREE LINK: https://t.co/3E5Si71Ef1 https://t.co/3E5Si71Ef1 - view on twitter
Mashup Score:167
Fred HutchFred Hutch launches MET-X, a ‘transformative approach to metastatic disease’ - 21 hours
Mashup Score:167
Fred Hutch translational researcher Dr. Cyrus Ghajar will lead a new Center for Metastasis Research Excellence, or MET-X, which will focus specifically on preventing,...
-
Not only is #metastaticcancer deadly, it is also one of, if not the most, challenging areas of cancer biology. Fred Hutch hopes to change that with the launch of the Center for Metastasis Research Excellence, or MET-X, led by @GhajarLab. https://t.co/ItlFz0ep6N - view on twitter
More coverage:
#metastaticcancer
Mashup Score:129
NatureMechanisms driving the immunoregulatory function of cancer cells – Nature Reviews Cancer - 1 week
Mashup Score:129
This Review outlines how the profound intertumoural heterogeneity in immune landscapes of tumours is shaped by cancer cell-intrinsic alterations and highlights how the crosstalk...
-
NEW content online! Mechanisms driving the immunoregulatory function of cancer cells https://t.co/H4sw0Yrhoz https://t.co/H4sw0Yrhoz - view on twitter
Mashup Score:96
NatureJäger and colleagues analyze single-base substitution and indel mutational signatures across 27 pediatric cancer types, revealing marked differences in mutational patterns compared with adult...
-
💫ONLINE NOW @NatureCancer – “Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers” #StefanMPfister #NatalieJäger @DKFZ @KiTZ_HD Read it here👇 https://t.co/agwMNqwpmM https://t.co/agwMNqwpmM - view on twitter
Mashup Score:77
NatureFendt and colleagues find that pre-metastatic niche formation and a high-fat diet increase palmitate availability in future organs of metastases and show that breast...
-
🔥Fascinating study on #metastasis @NatureCancer - “A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling” by @alteam_patricia @FendtLab & Co. Read it here👇 https://t.co/63blA7httX https://t.co/63blA7httX - view on twitter
More coverage:
#metastasis
Mashup Score:58
Annals of OncologyCirculating tumor DNA (ctDNA) sequencing is a promising approach for tailoring therapy in cancer patients. We report hereby the results from a prospective study...
-
In Annals of Oncology, a report on the STING (NCT04932525) study in which patients with advanced cancer had molecular profiling using a ctDNA sequencing assay 🩸🧬 and were assigned matched therapy 💊 as per a molecular tumor board. https://t.co/8iyqQ709Ks @GustaveRoussy @ArBayle - view on twitter
Mashup Score:55
The Lancet HaematologyThe chemotherapy-free combination of ponatinib and blinatumomab resulted in high rates of complete molecular response in patients with newly diagnosed and relapsed or refractory...
-
In the issue now: the chemotherapy-free combination of ponatinib and blinatumomab resulted in high rates of complete molecular response in newly diagnosed and r/r Ph-positive ALL @MDAndersonNews https://t.co/j3enrIZ4Z5 https://t.co/j3enrIZ4Z5 - view on twitter
Mashup Score:52
American Society of HematologyDistinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma - 2 days
Mashup Score:52
Key Points. B-ALL development in the setting of lenalidomide treatment for MM is a distinct primary malignancy with high incidence of TP53 mutations.Chronic...
-
Chronic lenalidomide therapy appears to be capable of expanding rare hematopoietic cells with acquired TP53 mutations. https://t.co/9IiGXUkz4l #lymphoidneoplasia https://t.co/9IiGXUkz4l - view on twitter
More coverage:
#lymphoidneoplasia
Summary:. Social media (SoMe) platforms have the ability to strengthen the oncology community, leading to intellectual connections that with time develop into friendships. SoMe...
RT @OncoAlert: The oncology community is growing stronger with the power of social media! 💻 https://t.co/3E5Si71Ef1 - view on twitter